arrow
J

James J. Harding

Memorial Sloan Kettering Cancer Center
H指数:53
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer

NRG1融合阳性实体瘤:临床检测、基因组景观及胰腺癌的真实世界数据

2025-12-130
OA
ASO Visual Abstract: Outcomes of First-versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

ASO视觉摘要:不可切除性肝内胆管癌中,一线与二线肝动脉灌注化疗的疗效比较

2025-11-170
PRE
Hepatocellular Carcinoma Growth Kinetics and Outcomes After Transarterial Embolization: A Single-Center Analysis

肝细胞癌生长动力学及经动脉栓塞术后结局:一项单中心分析

2025-10-170
OAAI
Outcomes of Transarterial Hepatic Embolization versus Yttrium-90 Radioembolization for Treatment of Patients with Hepatocellular Carcinoma >7 cm

经动脉肝栓塞与钇-90放射性栓塞治疗直径>7 cm肝细胞癌患者的疗效比较

2025-03-130
PRE
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma
2025-01-280
PRE
Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy
2024-09-271
PRE
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
2024-08-081
OAAI
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma
2024-08-080
OAAI
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial

通过FUZE多中心,开放标签,II期篮子试验评估FGFR融合阳性晚期实体瘤患者的Debio 1347

2024-05-211
PRE
ASO Visual Abstract: Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
2023-10-310
PRE
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
2023-10-097
OAAI